Evidence map›Paper›PMID 39922862›Full record

ArticleScientific reports2025

Characterization of visual cognition in pre-manifest, manifest and reduced penetrance Huntington's disease.

Rocío Del Pino, Maria Ángeles Acera, Amaia Ortiz de Echevarría, Beatriz Tijero, Marta Ruiz-Lopez, Johanne Somme, Javier Ruiz-Martínez, Andrea Gabilondo, Ioana M Croitoru, Lara Pardina and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Visual cognition as a marker of longitudinal disease progression in Huntington's disease.International journal of clinical and health psychology : IJCHP
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rocío Del PinoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain. delpinorocio@gmail.com.
Maria Ángeles AceraNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Amaia Ortiz de EchevarríaNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Beatriz TijeroNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Marta Ruiz-LopezNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Johanne SommeNeurology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.
Javier Ruiz-MartínezNeurology Department, Donostia University Hospital, San Sebastián, Gipuzkoa, Spain.
Andrea GabilondoOutpatient Mental Health Network of Gipuzkoa, San Sebastián, Spain.
Ioana M CroitoruNeurology Department, Donostia University Hospital, San Sebastián, Gipuzkoa, Spain.
Lara PardinaNeurology Department, Donostia University Hospital, San Sebastián, Gipuzkoa, Spain.
Naia Ayo-MentxakatorreNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Ane Murueta-GoyenaNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Iñigo GabilondoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Rosario Sanchez-PernauteNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Tamara Fernández-ValleNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.
Juan Carlos Gómez EstebanNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), Barakaldo, CP 48903, Spain.

Funding

EITB Maratoia BIO17/ND/009Health Department of the Basque Government 2019111004
6 · The paper itself

Abstract

Cognitive and visual impairment are common in Huntington's Disease (HD) and may precede motor diagnosis. We investigate the early presence of visual cognitive deficits in 181 participants, including HD carriers (40 pre-manifest, 30 early manifest, 27 manifest, and 6 reduced penetrance) and 78 healthy controls (HC). Significant differences in visual memory were observed between reduced penetrance and pre-manifest groups (p = .003), with pre-manifest showing worse performance. Age, education, CAG repeats, motor status, executive function, and verbal fluency, accounted for up to 72.8% of the variance in general and visual cognitive functions, with motor status having the strongest impact on visual domains in HD carriers. In pre-manifest HD, visual cognitive domains were primarily influenced by executive function, verbal fluency, age, and CAG repeats, while in early and manifest stages motor status and verbal fluency becomes more influential. ROC analyses showed that especially visuospatial abilities, visual memory, and visual attention (AUC = 0.927, 0.878, 0.874, respectively) effectively differentiated HC and pre-manifest from early and manifest HD. Early assessment of visual cognitive domains, particularly visual memory, could be an early marker of cognitive decline in HD. Our findings highlight the different profiles of impairment in visual cognition across HD carriers.

Indexed as

CognitionCognitive DysfunctionHuntington DiseaseAdultAgedCase-Control StudiesExecutive FunctionFemaleHumansMaleMiddle AgedNeuropsychological TestsPenetranceVisual PerceptionCognitionHuntington diseasePre-manifestReduced penetranceVisual cognition

Identifiers

PMID39922862
PMCPMC11807097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.